Related Experiment Video

Updated: Jun 13, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Growth retardation in children with cystinosis

M Besouw1, E Levtchenko

  • 1Department of Pediatric Nephrology, University Hospital Gasthuisberg, Leuven, Belgium.

Minerva Pediatrica
|May 15, 2010
PubMed

Insights

Cystinosis, a rare genetic disorder, causes cystine buildup, leading to kidney failure and growth issues in children. Early treatment with cysteamine and growth hormone can improve outcomes.

Area of Science:

  • Genetics
  • Pediatrics
  • Nephrology

Background:

  • Cystinosis is a rare autosomal recessive disorder caused by CTNS gene mutations, leading to cystine accumulation in lysosomes.
  • Infantile nephropathic cystinosis is the most severe form, causing renal Fanconi syndrome and end-stage renal failure by age 10 if untreated.
  • Cystine accumulation affects multiple organs, including eyes, muscles, CNS, and endocrine organs, contributing to multifactorial growth retardation.

Purpose of the Study:

  • To summarize the pathophysiology of cystinosis, focusing on its impact on growth and renal function.
  • To discuss current treatment strategies for cystinosis, including cysteamine and growth hormone therapy.
  • To highlight the persistent challenge of growth retardation in cystinosis patients despite therapeutic interventions.

Main Methods:

  • Literature review of cystinosis pathophysiology and treatment outcomes.
  • Analysis of factors contributing to growth retardation in affected children.
  • Evaluation of the efficacy of cysteamine and recombinant human growth hormone in managing cystinosis complications.

Main Results:

  • Cystinosis leads to progressive renal failure and affects multiple organ systems, significantly impacting growth.
  • Cysteamine treatment slows renal disease progression and protects extra-renal organs, while also promoting growth.
  • Despite treatment, growth retardation remains a significant complication, often necessitating recombinant human growth hormone administration.

Conclusions:

  • Cystinosis requires early and comprehensive management to mitigate severe complications like renal failure and growth failure.
  • Cysteamine is crucial for slowing disease progression and improving growth, emphasizing the need for early intervention.
  • Growth hormone therapy is often required to address persistent growth retardation in cystinosis patients, underscoring the complexity of managing this rare disorder.

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...